SAGE Therapeutics Company Profile (NASDAQ:SAGE)

About SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics logoSAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SAGE
  • CUSIP: N/A
  • Web: www.sagerx.com
Capitalization:
  • Market Cap: $2.55 billion
  • Outstanding Shares: 37,346,000
Average Prices:
  • 50 Day Moving Avg: $69.85
  • 200 Day Moving Avg: $59.31
  • 52 Week Range: $26.55 - $75.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.77
  • P/E Growth: 4.60
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $8.54 per share
  • Price / Book: 7.98
Profitability:
  • EBIDTA: ($186,560,000.00)
  • Return on Equity: -46.51%
  • Return on Assets: -43.72%
Debt:
  • Current Ratio: 19.47%
  • Quick Ratio: 19.47%
Misc:
  • Average Volume: 395,965 shs.
  • Beta: 2.73
  • Short Ratio: 5.66
 

Frequently Asked Questions for SAGE Therapeutics (NASDAQ:SAGE)

What is SAGE Therapeutics' stock symbol?

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How were SAGE Therapeutics' earnings last quarter?

SAGE Therapeutics Inc (NASDAQ:SAGE) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.61) by $0.09. View SAGE Therapeutics' Earnings History.

Where is SAGE Therapeutics' stock going? Where will SAGE Therapeutics' stock price be in 2017?

12 equities research analysts have issued 12 month price objectives for SAGE Therapeutics' shares. Their forecasts range from $60.00 to $110.00. On average, they anticipate SAGE Therapeutics' share price to reach $82.50 in the next year. View Analyst Ratings for SAGE Therapeutics.

What are analysts saying about SAGE Therapeutics stock?

Here are some recent quotes from research analysts about SAGE Therapeutics stock:

  • 1. BMO Capital Markets analysts commented, "We spoke with two leading psychiatrists who agreed that these data, while early, look great; they were particularly impressed with the magnitude of effect, early onset, strong remission rate, and overall safety for SAGE-217 in MDD. This profile is considered the 'holy grail' in treating depression. The physicians were also very optimistic regarding the prospects for SAGE-217 in a placebo-controlled trial for MDD given the large effect size in the open-label (one said 75-80% chance of success)' We are now including risk-adjusted sales for SAGE-217 in MDD of $25mn in 2021 ramping up to $325mn in 2027. We partially offset that with some increased expenses; the net result was that our EPS changed by $(0.51)-4.04 in 2017-27, and our target goes to $82 from $68." (2/22/2017)
  • 2. Chardan Capital analysts commented, "Yesterday, Sage Therapeutics announced encouraging top-line phase II results from its open label clinical trial of orally-administered SAGE-217 for major depressive disorder (MDD). Our discussions yesterday with industry participants in the depression space suggested a decidedly positive view of the SAGE-217 data. We now note that the SAGE-217 result follows what to us, in our 12 July 2016 research, was "potentially clear, positive" phase II data for IV SAGE-547 in severe postpartum depression (PPD). Although our 20 July 2016 questions on SAGE-547 remain unanswered, we are reassured by the granting of Breakthrough Therapy Designation (BTD) for SAGE-547 by the FDA and PRIME Designation by EMA, which both likely independently considered the issues we raised. Our initial 24 May 2016 bearish view on Sage was based largely on our expectations of phase III data for SAGE-547 in super-refractory status epilepticus (SRSE), which were originally due to read out in 2H16. The timing of the data has since moved to 1H17, exposing any SAGE-547 SRSE bear thesis to the upside potential surrounding SAGE-217 in MDD, and more limited potential of SAGE-547 in PPD. Indeed, we now see upside risk elsewhere in Sage and thereby upgrade from Sell to Neutral, raising our PT from $18 to $60." (2/14/2017)
  • 3. Cowen and Company analysts commented, "Today SAGE announced positive top-line results from its Ph2 OL trial of SAGE-217 in." (2/13/2017)
  • 4. Canaccord Genuity analysts commented, "We are encouraged by NDRM’s progress on its multiple development programs and continue to view the company’s approach to treating Parkinson’s disease as potentially paradigm-shifting. NDRM recently had an end of Ph2 meeting with the FDA to discuss ND0612 and has been allowed to move forward with PK equivalency in the US as opposed to doing a Ph3 efficacy trial. Additionally, NDRM announced positive top-line data from a pilot PK trial of ND0701 last week." (12/6/2016)
  • 5. According to Zacks Investment Research, "SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts. " (8/26/2016)

Who are some of SAGE Therapeutics' key competitors?

Who owns SAGE Therapeutics stock?

SAGE Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), BlackRock Inc. (7.68%), Vanguard Group Inc. (7.22%), Bank of New York Mellon Corp (5.52%), OppenheimerFunds Inc. (4.77%) and State Street Corp (3.02%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Stephen Kanes, Steven M Paul and Thomas Anderson. View Institutional Ownership Trends for SAGE Therapeutics.

Who sold SAGE Therapeutics stock? Who is selling SAGE Therapeutics stock?

SAGE Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Alliancebernstein L.P., JPMorgan Chase & Co., OppenheimerFunds Inc., UBS Asset Management Americas Inc., Eventide Asset Management LLC, BB Biotech AG and Morgan Stanley. Company insiders that have sold SAGE Therapeutics stock in the last year include Albert Robichaud and Kimi Iguchi. View Insider Buying and Selling for SAGE Therapeutics.

Who bought SAGE Therapeutics stock? Who is buying SAGE Therapeutics stock?

SAGE Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Point72 Asset Management L.P., Vanguard Group Inc., Emerald Advisers Inc. PA and Pictet Asset Management Ltd.. View Insider Buying and Selling for SAGE Therapeutics.

How do I buy SAGE Therapeutics stock?

Shares of SAGE Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of SAGE Therapeutics stock cost?

One share of SAGE Therapeutics stock can currently be purchased for approximately $68.15.

Analyst Ratings

Consensus Ratings for SAGE Therapeutics (NASDAQ:SAGE) (?)
Ratings Breakdown: 2 Hold Ratings, 9 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.92)
Consensus Price Target: $82.50 (21.06% upside)

Analysts' Ratings History for SAGE Therapeutics (NASDAQ:SAGE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Needham & Company LLCInitiated CoverageBuy -> Buy$82.00LowView Rating Details
5/12/2017Bank of America CorpInitiated CoverageBuy -> Buy$85.00HighView Rating Details
5/10/2017Canaccord GenuityReiterated RatingBuy$110.00MediumView Rating Details
4/3/2017JPMorgan Chase & Co.Reiterated RatingBuy$83.00HighView Rating Details
2/22/2017HC WainwrightDowngradeBuy -> Neutral$56.00 -> $76.00N/AView Rating Details
2/22/2017BMO Capital MarketsBoost Price TargetOutperform$68.00 -> $82.00N/AView Rating Details
2/14/2017Chardan CapitalUpgradeSell -> Neutral$60.00N/AView Rating Details
2/13/2017Cowen and CompanyReiterated RatingBuy$95.00N/AView Rating Details
12/14/2016Raymond James Financial, Inc.UpgradeOutperform -> Strong-Buy$84.00N/AView Rating Details
11/14/2016Stifel NicolausInitiated CoverageBuy$90.00N/AView Rating Details
10/4/2016Leerink SwannReiterated RatingOutperform$68.00N/AView Rating Details
7/15/2016William BlairReiterated RatingOutperform$75.00N/AView Rating Details
4/1/2016Goldman Sachs Group IncReiterated RatingBuy$63.00N/AView Rating Details
3/11/2016Lake Street CapitalInitiated CoverageBuy$90.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for SAGE Therapeutics (NASDAQ:SAGE)
Earnings by Quarter for SAGE Therapeutics (NASDAQ:SAGE)
Earnings History by Quarter for SAGE Therapeutics (NASDAQ:SAGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($1.61)($1.52)ViewListenView Earnings Details
2/23/2017Q4 2016($1.17)($1.50)ViewN/AView Earnings Details
11/3/2016Q316($1.10)($1.15)ViewN/AView Earnings Details
8/9/2016Q216($1.02)($1.08)ViewN/AView Earnings Details
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for SAGE Therapeutics (NASDAQ:SAGE)
2017 EPS Consensus Estimate: ($6.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.58)($1.49)($1.54)
Q2 20173($1.64)($1.50)($1.56)
Q3 20173($1.70)($1.43)($1.58)
Q4 20173($1.70)($1.45)($1.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for SAGE Therapeutics (NASDAQ:SAGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for SAGE Therapeutics (NASDAQ:SAGE)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 99.92%
Insider Trades by Quarter for SAGE Therapeutics (NASDAQ:SAGE)
Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)
Insider Trades by Quarter for SAGE Therapeutics (NASDAQ:SAGE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/13/2017Kimi IguchiCFOSell10,000$53.92$539,200.00View SEC Filing  
11/17/2016Kimi IguchiCFOSell4,000$51.77$207,080.00View SEC Filing  
11/11/2016Kimi IguchiCFOSell1,500$50.59$75,885.00View SEC Filing  
9/7/2016Kimi IguchiCFOSell2,500$40.93$102,325.00View SEC Filing  
7/12/2016Albert RobichaudInsiderSell22,000$40.00$880,000.00View SEC Filing  
7/12/2016Kimi IguchiCFOSell5,000$49.55$247,750.00View SEC Filing  
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.00View SEC Filing  
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.00View SEC Filing  
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00View SEC Filing  
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.00View SEC Filing  
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.00View SEC Filing  
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00View SEC Filing  
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.00View SEC Filing  
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for SAGE Therapeutics (NASDAQ:SAGE)
Latest Headlines for SAGE Therapeutics (NASDAQ:SAGE)
Source:
DateHeadline
finance.yahoo.com logoSage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder
finance.yahoo.com - May 18 at 11:35 AM
finance.yahoo.com logoBiotech Movers: Fast Track Designation Sends Sage Shares Higher
finance.yahoo.com - May 18 at 11:35 AM
streetinsider.com logoBioverativ Inc. (BIVV) Appoints Geno Germano to Board of Directors
www.streetinsider.com - May 15 at 6:53 PM
businesswire.com logoBioverativ Appoints Geno J. Germano to Company’s Board of Directors
www.businesswire.com - May 15 at 6:53 PM
americanbankingnews.com logoSAGE Therapeutics Inc (SAGE) Coverage Initiated by Analysts at Needham & Company LLC
www.americanbankingnews.com - May 15 at 5:42 PM
americanbankingnews.com logoSAGE Therapeutics Inc (SAGE) Coverage Initiated by Analysts at Bank of America Corp
www.americanbankingnews.com - May 13 at 12:32 AM
americanbankingnews.com logoSAGE Therapeutics Inc (SAGE) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 12 at 9:52 AM
americanbankingnews.com logoSAGE Therapeutics Inc (SAGE) Expected to Post Q2 2017 Earnings of ($1.50) Per Share
www.americanbankingnews.com - May 12 at 8:35 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for SAGE Therapeutics Inc (SAGE) Raised by William Blair
www.americanbankingnews.com - May 12 at 8:34 AM
americanbankingnews.com logoQ2 2017 Earnings Forecast for SAGE Therapeutics Inc Issued By Leerink Swann (SAGE)
www.americanbankingnews.com - May 12 at 8:34 AM
americanbankingnews.com logoFY2020 EPS Estimates for SAGE Therapeutics Inc Increased by Analyst (SAGE)
www.americanbankingnews.com - May 11 at 3:40 PM
americanbankingnews.com logoSAGE Therapeutics Inc (SAGE) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 6:40 PM
businesswire.com logoSage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update - Business Wire (press release)
www.businesswire.com - May 10 at 11:04 AM
americanbankingnews.com logoSAGE Therapeutics' (SAGE) Buy Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - May 10 at 7:36 AM
reuters.com logoBRIEF-Sage Therapeutics qtrly loss per share $1.52
www.reuters.com - May 9 at 7:11 PM
finance.yahoo.com logoSage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update
finance.yahoo.com - May 9 at 7:11 PM
marketbeat.com logoSage Therapeutics reports 1Q loss
marketbeat.com - May 9 at 4:19 PM
americanbankingnews.com logoSAGE Therapeutics (SAGE) Earns Daily Media Sentiment Score of 0.07
www.americanbankingnews.com - May 5 at 11:45 PM
americanbankingnews.com logoSAGE Therapeutics Inc (SAGE) Expected to Post Earnings of -$1.56 Per Share
www.americanbankingnews.com - May 4 at 8:14 AM
americanbankingnews.com logoSAGE Therapeutics (SAGE) Getting Somewhat Favorable Press Coverage, Study Finds
www.americanbankingnews.com - May 3 at 1:03 AM
businesswire.com logoSage Therapeutics Announces Initiation of Phase 1 Development ... - Business Wire (press release)
www.businesswire.com - April 27 at 8:07 PM
reuters.com logoBRIEF-Sage Therapeutics initiates phase 1 single ascending dose trial - Reuters
www.reuters.com - April 27 at 8:07 PM
finance.yahoo.com logoSage Therapeutics Announces Initiation of Phase 1 Development and First Dosing of SAGE-718
finance.yahoo.com - April 27 at 8:07 PM
businesswire.com logoSage Therapeutics to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017 - Business Wire (press release)
www.businesswire.com - April 26 at 8:59 PM
americanbankingnews.com logoSAGE Therapeutics (SAGE) Receives Media Impact Rating of 0.47
www.americanbankingnews.com - April 26 at 4:04 PM
cnbc.com logoCramer's lightning round: Buy, buy, buy this high-flying bank stock
www.cnbc.com - April 26 at 3:57 PM
streetinsider.com logoForm 3 Sage Therapeutics, Inc. For: Apr 24 Filed by: Cloonan Michael
www.streetinsider.com - April 26 at 3:57 PM
streetinsider.com logoForm 3 Sage Therapeutics, Inc. For: Apr 24 Filed by: Cloonan Michael - StreetInsider.com
www.streetinsider.com - April 26 at 9:30 AM
prnewswire.com logoHow These Biotech Stocks are Faring? -- Cymabay Therapeutics, Benitec Biopharma, Sage Therapeutics, and Catalyst ... - PR Newswire (press release)
www.prnewswire.com - April 26 at 9:30 AM
finance.yahoo.com logoCramer's lightning round: Buy, buy, buy this high-flying bank stock
finance.yahoo.com - April 26 at 9:30 AM
finance.yahoo.com logoSage Therapeutics to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017
finance.yahoo.com - April 25 at 6:44 PM
finance.yahoo.com logoSage Therapeutics Appoints Michael Cloonan as Chief Business Officer and Expands Executive Team
finance.yahoo.com - April 24 at 11:41 AM
americanbankingnews.com logoSAGE Therapeutics (SAGE) Receiving Favorable News Coverage, Report Shows
www.americanbankingnews.com - April 23 at 8:09 PM
americanbankingnews.com logoSAGE Therapeutics Sees Unusually High Options Volume (SAGE)
www.americanbankingnews.com - April 20 at 7:03 AM
nasdaq.com logoTrader makes bullish bet on Sage Therapeutics - Nasdaq
www.nasdaq.com - April 19 at 9:27 AM
finance.yahoo.com logoSage Therapeutics to Present at American Academy of Neurology 2017 Annual Meeting
finance.yahoo.com - April 19 at 9:27 AM
bizjournals.com logoMild Cognitive Impairment H1 2017 Pipeline Market Review and Therapeutics Development
www.bizjournals.com - April 17 at 6:41 PM
nasdaq.com logoNoteworthy Monday Option Activity: SAGE, THO, ATH
www.nasdaq.com - April 17 at 6:41 PM
americanbankingnews.com logoSAGE Therapeutics (SAGE) Given Daily Media Impact Score of 0.08
www.americanbankingnews.com - April 17 at 4:24 PM
americanbankingnews.com logoSAGE Therapeutics Inc (SAGE) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 17 at 11:03 AM
americanbankingnews.com logoCanaccord Genuity Analysts Give SAGE Therapeutics Inc (SAGE) a $110.00 Price Target
www.americanbankingnews.com - April 13 at 5:40 PM
finance.yahoo.com logoCramer's charts show these biotechs ignoring their 'political red herring'
finance.yahoo.com - April 11 at 7:26 PM
finance.yahoo.com logoCramer's charts show these biotechs ignoring their 'polit...
finance.yahoo.com - April 11 at 7:26 PM
americanbankingnews.com logoSAGE Therapeutics Inc (SAGE) Short Interest Down 5.7% in March
www.americanbankingnews.com - April 5 at 10:18 PM
americanbankingnews.com logoSAGE Therapeutics Inc (SAGE) Given a $83.00 Price Target at JPMorgan Chase & Co.
www.americanbankingnews.com - April 3 at 5:43 PM
finance.yahoo.com logoPershing Gold to Present at 2017 European Gold Forum
finance.yahoo.com - April 3 at 8:46 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Sage Therapeutics (SAGE) Stock?
finance.yahoo.com - March 30 at 7:55 PM
americanbankingnews.com logoSAGE Therapeutics Inc Expected to Post FY2019 Earnings of ($4.20) Per Share (SAGE)
www.americanbankingnews.com - March 27 at 9:57 AM
thestreet.com logoBiotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk - TheStreet.com
www.thestreet.com - March 25 at 8:25 AM
americanbankingnews.com logoSAGE Therapeutics Inc (SAGE) Given "Buy" Rating at Canaccord Genuity
www.americanbankingnews.com - March 21 at 9:25 PM

Social

Chart

SAGE Therapeutics (SAGE) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff